SCHEMBL2117553

SCHEMBL2117553

COc1ccc(N(C(C)c2ccccc2OC)S(=O)(=O)c2ccccc2F)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.44
ALDH1A1 P00352 3/20 0.42
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
PSEN1 P49768 6/20 0.39
PSEN2 P49810 6/20 0.39
APH1B Q8WW43 6/20 0.39
NCSTN Q92542 6/20 0.39
APH1A Q96BI3 6/20 0.39
PSENEN Q9NZ42 6/20 0.39
TSHR P16473 1/20 0.39
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
CES1 P23141 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120075 0.84 PSEN1 (0.44) HSD11B1ALDH1A1SMN1; SMN2PSEN1PSEN2
SCHEMBL2120059 0.81 PSEN1 (0.44) HSD11B1ALDH1A1LMNASMN1; SMN2PSEN1
SCHEMBL2117856 0.75 RECQL (0.46) HSD11B1ALDH1A1LMNASMN1; SMN2HCRTR2
SCHEMBL2119723 0.71 CA1 (0.40) LMNASMN1; SMN2PSEN1PSEN2APH1B
SCHEMBL2119805 0.71 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2PSEN1PSEN2APH1B
SCHEMBL2119628 0.71 PSEN1 (0.52) ALDH1A1PSEN1PSEN2APH1BNCSTN
SCHEMBL2117809 0.70 SMN1; SMN2 (0.40) LMNASMN1; SMN2PSEN1PSEN2APH1B
SCHEMBL2118315 0.69 PSEN1 (0.57) ALDH1A1LMNAPSEN1PSEN2APH1B
SCHEMBL2119849 0.68 HSD11B1 (0.50) HSD11B1PSEN1PSEN2APH1BNCSTN
SCHEMBL10249846 0.68 HSD11B1 (0.42) HSD11B1ALDH1A1SMN1; SMN2TSHRHCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 HSD11B1 3399/4885ALDH1A1 1996/4885LMNA 3339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.